title: Co-therapy with suboptimal doses of interleukin-12 and interferon-alpha promotes synergistic protection against herpes virus infection.
authors.affiliation: Department of Virology, Roche Research Centre, Herts, United Kingdom.
authors.forename: J A
authors.initials: JA
authors.lastname: Rogerson
authors.forename: D S
authors.initials: DS
authors.lastname: Pole
authors.forename: J A
authors.initials: JA
authors.lastname: Carr
authors.forename: N A
authors.initials: NA
authors.lastname: Roberts
authors.forename: A G
authors.initials: AG
authors.lastname: Lamont
mesh_terms: D000818:Animals; D004357:Drug Synergism; D006558:Herpes Genitalis / Q000276:immunology / Q000628:therapy*; D018258:Herpesvirus 2, Human; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage*; D018664:Interleukin-12 / Q000008:administration & dosage*; D051379:Mice; D008807:Mice, Inbred BALB C
chemical_list: D016898:Interferon-alpha; D018664:Interleukin-12